NCT04367870 (EVIDENCE) is a clinical trial in Oncology, sponsored by UNICANCER.

Who is sponsoring NCT04367870?

NCT04367870 is sponsored by UNICANCER.

Is NCT04367870 still recruiting?

NCT04367870 is currently completed. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT04367870: EVIDENCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Detection Test in Oncology

Completed Last updated 1 June 2022

What this trial tests

trial in Oncology in 441 participants. Completed in 30 April 2022.

Timeline

23 May 2020

Primary endpoint
31 May 2021

30 April 2022

Quick facts

Lead sponsor	UNICANCER
Status	Completed
Study type	OBSERVATIONAL
Enrollment	441
Start date	23 May 2020
Primary completion	31 May 2021
Estimated completion	30 April 2022
Sites	7 locations across France

Conditions studied

Oncology — all drugs for Oncology →

Sponsor

UNICANCER — full company profile →

Who can join

18 and older, any sex, with Oncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EVIDENCE is a non interventional, French, multicenter study. Patients will be screened by local severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoassay in their oncology department (rapid diagnostic test (RDT) or enzyme-linked immunosorbent assay (ELISA)). In patients with positive local SARS-CoV-2 immunoassay, a centralized SARS-CoV-2 ELISA will be performed in order to double check the immune response of all patients considered immune by local immunoassay.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
Impact of COVID-19 on Gynaecological oncology; a global perspective.
O'Neill D, El-Ghobashy A. · · 2021 · cited 3× · PMID 33829116 · DOI 10.1016/j.heliyon.2021.e06658

Verify or expand the search:

Other recruiting trials for Oncology

Currently open trials in the same condition.

NCT07341464 — Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends · NA · recruiting
NCT07262632 — Developing a Multimodal Cancer Pain Database to Support AI-Based Automatic Pain Assessment · recruiting
NCT06868524 — Leading Healthy Eating and Activity Promotion Program · NA · recruiting
NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting

Other UNICANCER trials

Trials by the same sponsor.

NCT07340619 — Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
NCT07360834 — Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndr · NA · not yet recruiting
NCT07106632 — Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests · Phase 3 · not yet recruiting
NCT07294430 — Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate. · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04367870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNICANCER
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04367870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing